RAZADYNE ER
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAZADYNE ER is an extended-release oral capsule small molecule approved in 2005. The indication and mechanism of action are not specified in available data. This product is a legacy branded formulation approaching loss of exclusivity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand teams should anticipate portfolio rotation and resource reallocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate limited hiring momentum on this brand. Working on RAZADYNE ER offers experience managing a mature, LOE-stage product but limited growth trajectory.
Brand ManagerMedical Science Liaison
Worked on RAZADYNE ER at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.